Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Magenta Therapeutics Inc (NQ: MGTA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Magenta Therapeutics Inc

MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cvent Holding Corp. (Nasdaq - CVT), Absolute Software Corporation (Nasdaq – ABST), Home Point Capital, Inc. (Nasdaq – HMPT), Magenta Therapeutics, Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)
From Brodsky & Smith LLC
Via GlobeNewswire
MGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
From Magenta Therapeutics
Via Business Wire
InvestorNewsBreaks – Magenta Therapeutics Inc. (NASDAQ: MGTA) Featured in Mizuho Securities Research Report
Via Investor Brand Network
Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
From Magenta Therapeutics, Inc.
Via Business Wire
Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
From Magenta Therapeutics, Inc.
Via Business Wire
Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference
From Magenta Therapeutics, Inc.
Via Business Wire
Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial
From Magenta Therapeutics, Inc.
Via Business Wire
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
From Magenta Therapeutics, Inc.
Via Business Wire
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
From Magenta Therapeutics, Inc.
Via Business Wire
Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
From Magenta Therapeutics, Inc.
Via Business Wire
Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
From Magenta Therapeutics, Inc.
Via Business Wire
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
From Magenta Therapeutics, Inc.
Via Business Wire
Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights
From Magenta Therapeutics
Via Business Wire
Magenta Therapeutics Appoints David Nichols as Chief Technical Officer
From Magenta Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.